SUNNYVALE, Calif., May 15, 2018 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S.
"Controlling the spread of carbapenemase-producing organisms in healthcare settings requires rapid recognition, coordinated surveillance, effective infection prevention activities, and a strong commitment to antimicrobial stewardship," said Dr. Fred C. Tenover, Cepheid's Vice President for Scientific Affairs and former Director of CDC's Office of Antimicrobial Resistance. "The addition of perirectal swab specimens to the product label should facilitate active surveillance testing programs, while the ability to use Xpert Carba-R results for therapeutic strategies should enhance antimicrobial stewardship efforts, especially in hospitals struggling with the spread of multidrug-resistant organisms."
Carbapenemase-producing CRE are currently believed to be primarily responsible for the increasing spread of CRE in the United States and have been targeted by the CDC for aggressive prevention measures.1 Detection and differentiation of high-risk patients with Xpert Carba-R can alert clinicians and infection preventionists quickly to the presence of gene sequences associated with carbapenem non-susceptibility in gram-negative bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Rapid detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences from pure colonies helps clinicians optimize patient management and direct therapeutic strategy. Perirectal and rectal swabs are not intended to direct therapeutic strategy.
About CepheidBased in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated molecular testing in virtually any setting. Through a strong foundation in innovation, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.
For Cepheid Media Inquiries: Darwa Peterson email@example.com
View original content:http://www.prnewswire.com/news-releases/fda-clears-expanded-claims-for-superbug-test-300648262.html
Subscribe to our Free Newsletters!
Tularemia is an uncommon, highly contagious bacterial infection acquired in humans by insect bites ...
Nipah Virus (NiV) or Hendra virus is a deadly virus that spreads via contact with the saliva, ...
Nose Bleeds or Epistaxis are common during summer. Here are simple tips to prevent nasal bleeding ...View All